NCT01280734已完成4 期
Randomised, Double-blind, 3-way Crossover, Single Dose, Placebo-controlled Study Investigating the Effect on Postural Instability of Melatonin and Zolpidem in Healthy Adult Subjects Aged of 55 to 64 Years.
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 26
- 试验地点
- 1
- 主要终点
- Body sway
研究概览
简要总结
This is a randomised, double-blind, 3-way crossover, single dose, placebo-controlled study investigating the effect on night time awakening body sway of melatonin and zolpidem in healthy adult subjects aged of 55 to 64 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 55 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •The subject must have signed an informed consent form.
- •The subject is a healthy man or woman. Women of child bearing potential or within two years of menopause must have negative urine pregnancy test at screening and use contraceptives as indicated in the protocol.
- •The subject is 55 to 64 years of age (extremes included).
- •The subject has a BMI >19 kg/m2 and < 30 kg/m2 at the Screening Visit.
- •The subject has a normal circadian rhythm, defined as a person who usually wakes between 06:00 and 09:00 and goes to sleep between 21:00 and 24:
- •The subject is, in the opinion of the investigator, generally healthy based on assessment of medical history and examination at screening
- •The subject is affiliated with, or beneficiary of a social security system.
排除标准
- •The subject has taken disallowed medication within 1 week prior to the first dose of IMP (or within 5 half-lives prior to admission for any medication ingested, whichever is longer). Disallowed medication is any prescribed medication or over-the-counter (OTC) medication as well as any herbal medicine known to interfere with the metabolic CYP pathways, such as St. John's Wort (except for hormonal contraceptives or hormonal substitution therapy). Subjects who have taken any non-prescribed systemic or topical medication may still be entered into the study if, in the opinion of the investigator, the medication will not interfere with the study procedures, study results, or compromise safety.
- •The subject weighs >136 kg.
- •The subject cannot stand erect and unsupported for more than 2 to 3 minutes or loses balance when standing on a fixed surface with eyes opened.
- •The subject has an excessive consumption of beverages on xanthine bases (more than 4 cups or glasses daily).
- •The subject has a presence or history of alcohol abuse defined as alcohol consumption greater than 21 units per week for men and greater than 14 units per week for women; or a presence or history of drug abuse within the last 6 months, or a history of substance abuse deemed relevant by the investigator.
- •The subject has taken any investigational products including these IMPs (zolpidem, melatonin) within 3 months prior to admission on Day
- •The subject has taken these IMPs earlier in this clinical study.
- •The subject has known hypersensitivity to the melatonin, zolpidem or their excipients.
- •The subject has a history of severe drug allergy or hypersensitivity.
- •The subject is pregnant or breastfeeding.
- •The subject has a presence or history of sleep disorder, fainting, cardiovascular diseases, carotid sinus syndrome, relevant dizziness or arrhythmia.
- •The subject has a history of or presence of any clinically relevant immunological, cardiovascular, pulmonary, metabolic, renal, hepatic, gastrointestinal, endocrinological, haematological, dermatological, venereal, neurological, systemic, ocular or psychiatric or infectious disease or other major disorder, or sign of acute illness.
- •The subject has a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin, which has not been in remission for at least 5 years before the first dose of IMP.
研究组 & 干预措施
Melatonin
Active Comparator
Circadin(R) 2 mg tablet 2 hours at 23:00
干预措施: Circadin (R) 2 mg (Drug)
Zolpidem
Active Comparator
Stilnox (R) 10 mg tablet at 23:00
干预措施: Stilnox (R) 10 mg (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Body sway
时间窗: 4 hours post IMP adminstration
次要结局
- Body Sway(1.5 hours post administration)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Abuse Potential Assessment of Intranasally Administered EMBEDA Compared To Morphine Sulfate Controlled Release And PlaceboNarcotic AbuseOpioid-related DisordersAnalgesiaChronic PainNCT01595867Pfizer33
已完成
4 期
Safety and Efficacy of IQP-LH-101 in Postprandial HeartburnPostprandial HeartburnNCT01718639InQpharm Group41
已完成
2 期
Efficacy of TPI ASM8 During a 14-Day Allergen ChallengeAsthmaNCT01158898Syntara16
已完成
2 期
A Study to Evaluate the Effect of Gefapixant (AF-219/MK-7264) on Methacholine Hyper-reactivity in Participants With Asthma (MK-7264-009)AsthmaNCT01993329Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)20
已完成
1 期
A Blinded, Dose Ascending Study to Assess the Pharmacokinetics, Safety and Tollerability of Repeat Inhaled Doses of Nebulised GW870086X in Healthy Adult Male Volunteers.AsthmaNCT01160003GlaxoSmithKline12